Auna (NYSE:AUNA) Given New $5.00 Price Target at JPMorgan Chase & Co.

Auna (NYSE:AUNA) had its target price decreased by research analysts at JPMorgan Chase & Co. from $6.00 to $5.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 18.76% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Auna in a research report on Friday, March 27th. Zacks Research cut Auna from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Wall Street Zen downgraded Auna from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.97.

Auna Trading Down 2.3%

Shares of NYSE:AUNA traded down $0.10 during trading on Tuesday, reaching $4.21. 369,498 shares of the company traded hands, compared to its average volume of 408,340. The company has a current ratio of 1.09, a quick ratio of 1.01 and a debt-to-equity ratio of 1.76. Auna has a 52-week low of $4.15 and a 52-week high of $6.97. The firm has a market capitalization of $311.58 million, a price-to-earnings ratio of 16.19 and a beta of 1.03. The business’s fifty day moving average is $5.32 and its 200-day moving average is $5.05.

Auna (NYSE:AUNA) last issued its earnings results on Tuesday, May 19th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.14). The firm had revenue of $336.84 million during the quarter, compared to analysts’ expectations of $320.54 million. Auna had a return on equity of 16.25% and a net margin of 1.53%. As a group, analysts forecast that Auna will post 0.85 EPS for the current year.

Institutional Trading of Auna

Institutional investors and hedge funds have recently bought and sold shares of the stock. World Investment Advisors boosted its position in Auna by 19.1% during the 1st quarter. World Investment Advisors now owns 12,563 shares of the company’s stock valued at $69,000 after acquiring an additional 2,014 shares in the last quarter. Virtu Financial LLC raised its position in shares of Auna by 43.5% in the 4th quarter. Virtu Financial LLC now owns 16,029 shares of the company’s stock worth $79,000 after acquiring an additional 4,856 shares in the last quarter. Sage Investment Counsel LLC lifted its stake in shares of Auna by 60.0% in the 4th quarter. Sage Investment Counsel LLC now owns 16,000 shares of the company’s stock valued at $79,000 after purchasing an additional 6,000 shares during the period. Citadel Advisors LLC lifted its stake in shares of Auna by 28.9% in the 3rd quarter. Citadel Advisors LLC now owns 36,352 shares of the company’s stock valued at $244,000 after purchasing an additional 8,147 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Auna by 255.9% during the first quarter. Bank of America Corp DE now owns 16,886 shares of the company’s stock valued at $93,000 after purchasing an additional 12,142 shares in the last quarter.

About Auna

Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.

The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.